Free Trial

Jefferies Financial Group's Rating of Gyre Therapeutics on 10/10/2025

On October 10, 2025, Jefferies Financial Group updated its outlook on Gyre Therapeutics (NASDAQ:GYRE) with the action "Initiated Coverage", setting a "Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Jefferies Financial Group Inc.

DateCompanyAction
10/10/2025
Essential Utilities Inc. stock logo
WTRG
Essential Utilities
Boost Price Target
10/10/2025
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
Initiated Coverage
10/10/2025
PepsiCo, Inc. stock logo
PEP
PepsiCo
Boost Price Target
10/10/2025
CME Group Inc. stock logo
CME
CME Group
Lower Price Target
10/10/2025
Pony AI Inc. - Sponsored ADR stock logo
PONY
Pony AI
Initiated Coverage
10/10/2025
Valero Energy Corporation stock logo
VLO
Valero Energy
Boost Price Target
More Ratings From Jefferies Financial Group Inc.